Alba Rubio‐San‐Simón

Daratumumab in pediatric relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: the DELPHINUS study

Teena Bhatla, Laura Hogan, David T. Teachey et al. · Blood · 2024 · 40 citations · Full text

BEACON-Immuno: Results of the dinutuximab beta (dB) randomization of the BEACON-Neuroblastoma phase 2 trial—A European Innovative Therapies for Children with Cancer (ITCC–International Society of Paediatric Oncology Europe Neuroblastoma Group (SIOPEN) trial.

Juliet C. Gray, Lucas Moreno, Rebekah Weston et al. · Journal of Clinical Oncology · 2022 · 29 citations

Db Randomisation, Beacon-neuroblastoma Phase 2, Chemo-immunotherapy Randomisation +15

Impact of COVID-19 in paediatric early-phase cancer clinical trials in Europe: A report from the Innovative Therapies for Children with Cancer (ITCC) consortium

Alba Rubio‐San‐Simón, Nicolás André, Maria Giuseppina Cefalo et al. · European Journal of Cancer · 2020 · 22 citations · Full text

Long Covid, Medicine, Global Health +7

Inotuzumab ozogamicin combined with chemotherapy in pediatric B-cell precursor CD22<sup>+</sup> acute lymphoblastic leukemia: results of the phase IB ITCC-059 trial

Edoardo Pennesi, Erica Brivio, Anneke C. J. Ammerlaan et al. · Haematologica · 2024 · 17 citations · Full text

The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trial

Jaume Mora, Daniel A. Morgenstern, Loredana Amoroso et al. · Nature Communications · 2025 · 17 citations · Full text